J. Goldman & Co’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

J. Goldman & Co’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-256,245	Closed	-$177K	–	622
2020 Q4	$177K	Buy	+256,245	New	+$546K	0.01%	334

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

J. Goldman & Co's BMY.RT Position: Q1 2021 in Review

J. Goldman & Co sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 256,245 shares — an estimated $177K sold.

J. Goldman & Co first reported a position in BMY.RT in Q4 2020 and held it in 1 quarter. The position peaked at $177K in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

J. Goldman & Co reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
J. Goldman & Co sold 256,245 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $177K.
J. Goldman & Co first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2020 and held it in 1 quarter.
J. Goldman & Co's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $177K in Q4 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on J. Goldman & Co's 13F filing for Q1 2021, filed 17 May 2021.